Pancreatic Cancer Research

ResearcherUniversity of Chieti-PescaraActive in the last 2 years

Ilario Giovanni Rapposelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1802-5671; OpenAlex author ID A5043332769. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
81
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 6 papers · 2022: none · 2023: 5 papers · 2024: none · 2025: 3 papers · 2026: 3 papers

Papers 18

  1. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  2. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  3. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  4. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  5. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Co-author DOI 10.1016/j.dld.2024.06.025↗
  6. A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemothe… Co-author DOI 10.1016/j.dld.2025.11.007↗
  7. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  8. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  9. Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value. Last author DOI 10.1016/j.omtm.2023.05.009↗
  10. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  11. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  12. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  13. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  14. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic can… Co-author DOI 10.1186/s12885-021-08368-5↗
  15. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/biom11060780↗
  16. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. First author DOI 10.3390/biom11081200↗
  17. Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight. Co-author DOI 10.3390/ijms23010254↗
  18. Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. First author DOI 10.1038/oncsis.2014.31↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Macchini · 9 shared papers, 2021–2026 · strength 1.45
  2. Giulia Orsi · 9 shared papers, 2021–2026 · strength 1.45
  3. Michele Reni · 9 shared papers, 2021–2026 · strength 1.45
  4. Michèle Milella · 9 shared papers, 2021–2026 · strength 1.38
  5. Letizia Procaccio · 7 shared papers, 2023–2026 · strength 1.27
  6. Mariacristina Di Marco · 7 shared papers, 2021–2026 · strength 1.11
  7. Silvia Bozzarelli · 7 shared papers, 2021–2026 · strength 1.10
  8. Sara Lonardi · 5 shared papers, 2023–2026 · strength 0.84
  9. Mario Scartozzi · 5 shared papers, 2021–2026 · strength 0.80
  10. Guido Giordano · 6 shared papers, 2021–2025 · strength 0.80
  11. Stefano Cascinu · 6 shared papers, 2021–2025 · strength 0.80
  12. Giuseppe Malleo · 4 shared papers, 2023–2026 · strength 0.77
  13. Monica Niger · 6 shared papers, 2021–2025 · strength 0.76
  14. Massimo Falconi · 4 shared papers, 2021–2026 · strength 0.74
  15. Elisa Giommoni · 5 shared papers, 2021–2025 · strength 0.67
  16. Lisa Salvatore · 5 shared papers, 2021–2025 · strength 0.67
  17. Catia Carconi · 3 shared papers, 2026 · strength 0.65
  18. Umberto Peretti · 5 shared papers, 2021–2025 · strength 0.64
  19. Giampaolo Tortora · 5 shared papers, 2021–2025 · strength 0.60
  20. Francesca Bergamo · 3 shared papers, 2025–2026 · strength 0.54
  21. Ingrid Garajová · 4 shared papers, 2021–2025 · strength 0.53
  22. Alessandro Passardi · 4 shared papers, 2021–2023 · strength 0.51
  23. Maria Grazia Rodriquenz · 4 shared papers, 2021–2025 · strength 0.46
  24. Diego Palumbo · 2 shared papers, 2026 · strength 0.44
  25. Andrea Spallanzani · 3 shared papers, 2021–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.